Cortico-dependence is frequent in giant cell arteritis patients, and no drugs has proved its
ability to prevent corticodependence. Hydrocychloroquine is a well tolerated immunomodulatory
drug that may have a corticosteroid sparing potential according to immuno-pharmacological and
clinical data. We have designed a multcentric double blind versus placebo randomized
controled trial to assess the corticosteroid sparing effect of hydroxychloroquine in non
complicated giant cell arteritis.